Serum interferon in systemic lupus erythematosus.

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by widespread inflammation.
• The role of interferons in the pathogenesis of SLE is an area of ongoing research.

Purpose of the Study:

• To investigate serum interferon levels in patients with SLE.
• To correlate interferon levels with disease activity, clinical manifestations, and serological markers.
• To evaluate the potential therapeutic implications of interferon in SLE.

Main Methods:

• Serum samples from 47 SLE patients (67 samples total) were analyzed for interferon levels.
• Interferon levels were compared between active and quiescent disease states.
• Correlations with clinical features (skin lesions, arthritis, renal/hematopoietic involvement), ANA titre, C3, and immune complexes were assessed.

Main Results:

• Increased serum interferon levels were detected in 72% of SLE patients and 70% of samples.
• Elevated interferon levels were significantly more prevalent in patients with active disease (81%) compared to quiescent disease (10%).
• Interferon levels correlated directly with ANA titre and inversely with C3 levels, and were associated with specific clinical manifestations.

Conclusions:

• Serum interferon levels serve as a valuable biomarker for SLE disease activity and may predict prognosis.
• Type alpha interferon was identified as the predominant type in SLE patients.
• Given potential involvement in SLE pathophysiology, interferon or its inducers are not recommended for SLE therapy.